Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
Saved in:
| Published in | British Journal of Haematology Vol. 182; no. 4; pp. 583 - 586 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley
01.08.2018
Blackwell Publishing Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | Kiyoshi Ando Michinori Ogura Nam H. Dang John Radford Michael Shnaidman Paul A. Hamlin Kensei Tobinai Erik Vandendries Radhakrishnan Ramchandren Luis E. Fayad Douglas A. Stewart Eva Giné Igor Bondarenko Antonio Pezzutto Sharon Sullivan Mats Jerkeman Sylvie Castaigne |
|---|---|
| AuthorAffiliation | 11 Pfizer Inc, Cambridge, MA, USA 15 Hospital Clínic, Barcelona, Spain 8 Charité-Universitätsmedizin, Berlin, Germany 2 Nagoya Daini Red Cross Hospital, Nagoya, Japan 1 University of Florida, Gainesville, FL, USA 3 Tokai Central Hospital, Kakamigahara, Japan 14 Memorial Sloan Kettering Cancer Center, New York, NY, USA 12 National Cancer Centre Hospital, Tokyo, Japan 4 University of Versailles Saint-Quentin, Le Chesnay, France 7 University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK 10 University of Calgary, Calgary, AB, Canada 13 Karmanos Cancer Center, Detroit, MI, USA 6 Lund University, Lund, Sweden 9 State Medical Academy, Dnepropetrovsk, Ukraine 16 Tokai University, School Medicine, Isehara, Kanagawa, Japan 5 University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| AuthorAffiliation_xml | – name: 11 Pfizer Inc, Cambridge, MA, USA – name: 16 Tokai University, School Medicine, Isehara, Kanagawa, Japan – name: 5 University of Texas MD Anderson Cancer Center, Houston, TX, USA – name: 13 Karmanos Cancer Center, Detroit, MI, USA – name: 6 Lund University, Lund, Sweden – name: 10 University of Calgary, Calgary, AB, Canada – name: 7 University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK – name: 8 Charité-Universitätsmedizin, Berlin, Germany – name: 12 National Cancer Centre Hospital, Tokyo, Japan – name: 1 University of Florida, Gainesville, FL, USA – name: 2 Nagoya Daini Red Cross Hospital, Nagoya, Japan – name: 15 Hospital Clínic, Barcelona, Spain – name: 3 Tokai Central Hospital, Kakamigahara, Japan – name: 4 University of Versailles Saint-Quentin, Le Chesnay, France – name: 14 Memorial Sloan Kettering Cancer Center, New York, NY, USA – name: 9 State Medical Academy, Dnepropetrovsk, Ukraine |
| Author_xml | – sequence: 1 givenname: Nam H. surname: Dang fullname: Dang, Nam H. email: nam.dang@medicine.ufl.edu organization: University of Florida – sequence: 2 givenname: Michinori surname: Ogura fullname: Ogura, Michinori organization: Tokai Central Hospital – sequence: 3 givenname: Sylvie surname: Castaigne fullname: Castaigne, Sylvie organization: University of Versailles Saint‐Quentin – sequence: 4 givenname: Luis E. surname: Fayad fullname: Fayad, Luis E. organization: University of Texas MD Anderson Cancer Center – sequence: 5 givenname: Mats surname: Jerkeman fullname: Jerkeman, Mats organization: Lund University – sequence: 6 givenname: John surname: Radford fullname: Radford, John organization: Manchester Academic Health Science Centre – sequence: 7 givenname: Antonio surname: Pezzutto fullname: Pezzutto, Antonio organization: Charité‐Universitätsmedizin – sequence: 8 givenname: Igor surname: Bondarenko fullname: Bondarenko, Igor organization: State Medical Academy – sequence: 9 givenname: Douglas A. surname: Stewart fullname: Stewart, Douglas A. organization: University of Calgary – sequence: 10 givenname: Michael surname: Shnaidman fullname: Shnaidman, Michael organization: Pfizer Inc – sequence: 11 givenname: Sharon orcidid: 0000-0002-4327-666X surname: Sullivan fullname: Sullivan, Sharon organization: Pfizer Inc – sequence: 12 givenname: Erik surname: Vandendries fullname: Vandendries, Erik organization: Pfizer Inc – sequence: 13 givenname: Kensei surname: Tobinai fullname: Tobinai, Kensei organization: National Cancer Centre Hospital – sequence: 14 givenname: Radhakrishnan surname: Ramchandren fullname: Ramchandren, Radhakrishnan organization: Karmanos Cancer Center – sequence: 15 givenname: Paul A. surname: Hamlin fullname: Hamlin, Paul A. organization: Memorial Sloan Kettering Cancer Center – sequence: 16 givenname: Eva surname: Giné fullname: Giné, Eva organization: Hospital Clínic – sequence: 17 givenname: Kiyoshi surname: Ando fullname: Ando, Kiyoshi organization: Tokai University |
| BackLink | https://cir.nii.ac.jp/crid/1874242817475714816$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/28677896$$D View this record in MEDLINE/PubMed https://lup.lub.lu.se/record/03ca04e0-8db7-4914-9f9e-6bef9df5642c$$DView record from Swedish Publication Index oai:portal.research.lu.se:publications/03ca04e0-8db7-4914-9f9e-6bef9df5642c$$DView record from Swedish Publication Index |
| BookMark | eNqNks1u1DAUhSNUREvpghdAkWABEtPajuOfDRKtgIJGQkLdW45zM3Fx4mAnU2ZWPAJvwXvxJHg6bUUrFREpcRJ_99xj-zzOdnrfQ5Y9xegQp-uoOm8PMRUEPcj2cMHKGcEU72R7CCE-w4iK3ewgRlul70LggqBH2S4RjHMh2V7264vua9_ZNdSv86HVEfIiH4PVLvdNbns_Tuup01Xu136hO2tsnw9uinmw4_TdbmaWEGL6YVro_NhC0MPqLtL4kAdweohQHwVogjajD6tcLxYBkrkl5Me_f_w04FyelpdeT329-Jp6uVU3tL7TT7KHjXYRDq7G_ezs_buzk9PZ_POHjydv5zPDJEczLGmhtaY14UAkUMnLsmKUc8yR4UQ3BgTSktSCCSMkFCBMbUqhNWsMlcV-prey8QKGqVJDSP7DSnlt1eDDqJ1KhkEH0yo3qQgqUc4aPVrfR4UKoxEFpERdcUUlpko2EhSroJF1UzJKTOoxv7eHm4Z0V1fa_yn3ZiuXtDqoDfRjSDZvOb8109tWLfxSMZISQYsk8PJKIPhvE8RRdTZujkL34KeosMSsEKgUG_T5HfTcT6FPB6IIElwIRhhO1LO_Hd1YuU5dAl5tARN8jCkPNwhGahNqlUKtLkOd2KM7rLHj5XanxVj3r4oL62B1v7Q6_nR6XfFiW9Fbm-Q3Tyw4JZQIzCkvecLSHvwBydwagg |
| CitedBy_id | crossref_primary_10_1186_s13045_021_01097_z crossref_primary_10_1080_10428194_2023_2234528 crossref_primary_10_2174_1574892818666230117151757 crossref_primary_10_1097_PPO_0000000000000631 crossref_primary_10_1186_s13045_024_01552_7 crossref_primary_10_1007_s11523_018_0558_1 crossref_primary_10_2147_ITT_S288546 crossref_primary_10_3390_curroncol28010027 crossref_primary_10_3390_cells12141858 crossref_primary_10_1007_s40259_021_00491_w crossref_primary_10_1111_bjh_15734 crossref_primary_10_1080_17474086_2022_2044778 crossref_primary_10_37349_etat_2022_00112 crossref_primary_10_1016_S2352_3026_20_30065_X crossref_primary_10_1016_j_hemonc_2021_07_002 crossref_primary_10_1186_s13045_019_0786_6 crossref_primary_10_1111_bjh_16461 crossref_primary_10_3390_biology10111178 crossref_primary_10_1002_cam4_4052 crossref_primary_10_1038_s41392_020_0113_2 crossref_primary_10_3389_fonc_2024_1396395 crossref_primary_10_1016_j_pharmthera_2021_107917 crossref_primary_10_1186_s13045_020_01011_z crossref_primary_10_3390_cancers14081917 crossref_primary_10_1002_hep_30222 crossref_primary_10_1007_s11899_018_0485_3 crossref_primary_10_1200_EDBK_279043 crossref_primary_10_4143_crt_2022_1658 crossref_primary_10_1080_17474086_2020_1795828 crossref_primary_10_1016_S2352_3026_19_30026_2 crossref_primary_10_1172_JCI129206 crossref_primary_10_1007_s12325_020_01507_7 crossref_primary_10_1016_j_clml_2018_05_006 crossref_primary_10_1080_14796694_2024_2357537 crossref_primary_10_1002_cncr_35505 crossref_primary_10_1002_ptr_8407 crossref_primary_10_1177_1758835920962997 crossref_primary_10_1080_10428194_2021_1966780 crossref_primary_10_1186_s13045_020_00914_1 crossref_primary_10_1053_j_seminhematol_2023_11_001 crossref_primary_10_1002_hon_3029 crossref_primary_10_4103_jcrt_jcrt_269_24 crossref_primary_10_6004_jnccn_2020_7608 crossref_primary_10_1093_jncics_pkad069 crossref_primary_10_1111_bjh_18384 crossref_primary_10_2174_1573394719666230201122212 crossref_primary_10_3390_cancers14030626 crossref_primary_10_1182_bloodadvances_2018026211 crossref_primary_10_1016_j_hoc_2019_03_007 crossref_primary_10_1002_mco2_671 |
| Cites_doi | 10.1200/JCO.2012.42.7211 10.1200/JCO.2009.25.1900 10.1111/j.1349-7006.2010.01601.x 10.1111/j.1349-7006.2012.02241.x 10.1158/1078-0432.CCR-15-2488 |
| ContentType | Journal Article |
| Copyright | 2017 John Wiley & Sons Ltd Copyright © 2018 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2017 John Wiley & Sons Ltd – notice: Copyright © 2018 John Wiley & Sons Ltd |
| CorporateAuthor | Tumor microenvironment Institutionen för kliniska vetenskaper, Lund Lunds universitet Medical oncology Lund University Medicinsk onkologi Tumörmikromiljö Department of Clinical Sciences, Lund Section I Lymfom - Klinisk forskning Faculty of Medicine Lymphoma - Clinical Research Sektion I Medicinska fakulteten |
| CorporateAuthor_xml | – name: Faculty of Medicine – name: Medicinska fakulteten – name: Institutionen för kliniska vetenskaper, Lund – name: Section I – name: Lunds universitet – name: Sektion I – name: Department of Clinical Sciences, Lund – name: Lymfom - Klinisk forskning – name: Tumörmikromiljö – name: Lund University – name: Medical oncology – name: Tumor microenvironment – name: Lymphoma - Clinical Research – name: Medicinsk onkologi |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 5PM ADTPV AOWAS BTSUP D95 |
| DOI | 10.1111/bjh.14820 |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SwePub Editorial SWEPUB Lunds universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2141 |
| EndPage | 586 |
| ExternalDocumentID | oai_portal_research_lu_se_publications_03ca04e0_8db7_4914_9f9e_6bef9df5642c oai_lup_lub_lu_se_03ca04e0_8db7_4914_9f9e_6bef9df5642c PMC6200343 28677896 10_1111_bjh_14820 BJH14820 |
| Genre | letter Letter Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Pfizer Inc – fundername: NCI NIH HHS grantid: R01 CA152923 – fundername: NCI NIH HHS grantid: P30 CA016672 |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 1OB 1OC 23N 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGYGG AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HGLYW HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 RYH SUPJJ TEORI UB1 V8K V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH YOC YUY ZZTAW ~IA ~WT .55 .GJ .Y3 1KJ 24P 31~ 3O- 8F7 AAKAS AANHP ACBWZ ACRPL ACYXJ ADNMO ADZCM AEUQT AFFNX AFPWT AHEFC AI. ASPBG AVWKF AZFZN CAG COF EGARE ESX FEDTE FZ0 HF~ HVGLF N4W PALCI RIWAO RJQFR SAMSI VH1 WRC WUP X7M ZGI ZXP AAYXX AGQPQ CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 5PM ADTPV AOWAS BTSUP D95 |
| ID | FETCH-LOGICAL-c6970-1943aaa4d27e29e49755b6477170c72afce80a92d868c89e3e8cdc58aa6fc493 |
| IEDL.DBID | DR2 |
| ISSN | 0007-1048 1365-2141 |
| IngestDate | Thu Aug 21 06:31:52 EDT 2025 Thu Jul 03 05:08:18 EDT 2025 Thu Aug 21 17:41:21 EDT 2025 Fri Jul 11 00:07:01 EDT 2025 Fri Jul 25 10:06:21 EDT 2025 Mon Jul 21 05:59:46 EDT 2025 Tue Jul 01 02:05:59 EDT 2025 Thu Apr 24 23:01:28 EDT 2025 Wed Jan 22 16:52:18 EST 2025 Fri Jun 27 00:05:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | B-cell non-Hodgkin lymphoma antibody-drug conjugate inotuzumab ozogamicin CD22 rituximab |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6970-1943aaa4d27e29e49755b6477170c72afce80a92d868c89e3e8cdc58aa6fc493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Correspondence-3 content type line 23 ObjectType-Undefined-4 NHD, MO, SC, LEF, MJ, JR, AP, IB, DAS, KT, RR, PAH, EG and KA participated in the collection, interpretation and analysis of data and the development of the manuscript draft. MS, SS and EV participated in study design, the interpretation and analysis of data and the development of the manuscript Author contributions |
| ORCID | 0000-0001-9500-1804 0000-0002-7071-2471 0000-0001-7898-2786 0000-0002-3246-4470 0000-0002-4327-666X |
| OpenAccessLink | https://cir.nii.ac.jp/crid/1874242817475714816 |
| PMID | 28677896 |
| PQID | 2087886261 |
| PQPubID | 36395 |
| PageCount | 4 |
| ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_03ca04e0_8db7_4914_9f9e_6bef9df5642c swepub_primary_oai_lup_lub_lu_se_03ca04e0_8db7_4914_9f9e_6bef9df5642c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6200343 proquest_miscellaneous_1916380583 proquest_journals_2087886261 pubmed_primary_28677896 crossref_primary_10_1111_bjh_14820 crossref_citationtrail_10_1111_bjh_14820 wiley_primary_10_1111_bjh_14820_BJH14820 nii_cinii_1874242817475714816 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | August 2018 |
| PublicationDateYYYYMMDD | 2018-08-01 |
| PublicationDate_xml | – month: 08 year: 2018 text: August 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | British Journal of Haematology |
| PublicationTitleAlternate | Br J Haematol |
| PublicationYear | 2018 |
| Publisher | Wiley Blackwell Publishing Ltd |
| Publisher_xml | – name: Wiley – name: Blackwell Publishing Ltd |
| References | 2012; 103 2010; 28 2013; 31 2010; 101 2016; 22 e_1_2_5_4_1 e_1_2_5_3_1 e_1_2_5_2_1 e_1_2_5_6_1 e_1_2_5_5_1 |
| References_xml | – volume: 31 start-page: 573 year: 2013 end-page: 583 article-title: Safety and clinical activity of a combination therapy comprising two antibody‐based targeting agents for the treatment of non‐Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab publication-title: Journal of Clinical Oncology – volume: 103 start-page: 933 year: 2012 end-page: 938 article-title: Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma publication-title: Cancer Science – volume: 28 start-page: 2085 year: 2010 end-page: 2093 article-title: Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B‐cell non‐Hodgkin's lymphoma: results of a phase I study publication-title: Journal of Clinical Oncology – volume: 101 start-page: 1840 year: 2010 end-page: 1845 article-title: Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy publication-title: Cancer Science – volume: 22 start-page: 4807 year: 2016 end-page: 4816 article-title: Phase I study of inotuzumab ozogamicin combined with R‐CVP for relapsed/refractory CD22+ B‐cell non‐Hodgkin lymphoma publication-title: Clinical Cancer Research – ident: e_1_2_5_3_1 doi: 10.1200/JCO.2012.42.7211 – ident: e_1_2_5_2_1 doi: 10.1200/JCO.2009.25.1900 – ident: e_1_2_5_4_1 doi: 10.1111/j.1349-7006.2010.01601.x – ident: e_1_2_5_5_1 doi: 10.1111/j.1349-7006.2012.02241.x – ident: e_1_2_5_6_1 doi: 10.1158/1078-0432.CCR-15-2488 |
| SSID | ssib000381320 ssib000829637 ssib020716558 ssib006541687 ssib020716559 ssj0013051 ssib006541688 ssib058492421 ssib020716560 ssib001235816 |
| Score | 2.4709659 |
| SourceID | swepub pubmedcentral proquest pubmed crossref wiley nii |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 583 |
| SubjectTerms | Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibody-drug conjugate Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects B-cell non-Hodgkin lymphoma Cancer and Oncology Cancer och onkologi CD22 Chemotherapy Clinical Medicine Female Hematology Humans Immunotherapy Inotuzumab ozogamicin Klinisk medicin Letter Lymphocytes B Lymphoma Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - mortality Lymphoma, B-Cell - pathology Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Monoclonal antibodies Non-Hodgkin's lymphoma ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre Rituximab Rituximab - administration & dosage Rituximab - adverse effects Targeted cancer therapy |
| Title | Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma |
| URI | https://cir.nii.ac.jp/crid/1874242817475714816 https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.14820 https://www.ncbi.nlm.nih.gov/pubmed/28677896 https://www.proquest.com/docview/2087886261 https://www.proquest.com/docview/1916380583 https://pubmed.ncbi.nlm.nih.gov/PMC6200343 https://lup.lub.lu.se/record/03ca04e0-8db7-4914-9f9e-6bef9df5642c oai:portal.research.lu.se:publications/03ca04e0-8db7-4914-9f9e-6bef9df5642c |
| Volume | 182 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKD4gL_9CFFhnEoQdS8mPHtjhR1GpVqRyqIlUIybIdZzd0N4k2G4ndE4_AW_BePAnjJBu6ZZEqDllF8WSSzI7HM_b4G4ReKxiSwW9VnrZB7BFCQ09oQ71AEWZiYQKlXaB4-jEefiInF_RiC71b7YVp8SH6CTfXMxp77Tq40tWVTq6_jg8ciKWL112ulnOIzsI_Kwg-7arlMTA1hHeoQi6Lp79zbSy6lWfZJjfz72zJDlN03Z1txqPje-jL6kvaNJTLg3quD8zyGsjjf37qfXS381Px-1axHqAtmz9Et0-7lfhH6OeZypNimi1t8gaXYxgLcYSbEiC4SHGWF_N6WU-VxsWyGLma91mOy0ld4Vk2r79lrsUlhMAF0Jpptw1scZ0EPGrsdtuUlU3egvxmTXWgBVajZpoALDU-_PX9h1t9wHmRw-mwSEaX8KzJAtS0mKrH6Pz46PzD0OuKPnigGsz3AkEipRRJQmZDYYlglGq3WzZgvmGhSo3lvhJhwmNuuLCR5SYxlCsVp4aI6AnahufZHYStoCoKQd2MKztIU2AqNONWMG19FQUDtL_696XpANFdXY6JXAVGIHfZyH2AXvWkZYsCsoloD1QIWLlfV-oQvB8OAR-jDNqDeIB2V8olO0NRydDnjLuoEl7nZd8MXdxJTuW2qCsJITVYSZ_yaICetrrYv0Xo8Ai5AOZsTUt7Agcfvt6SZ-MGRjx2eYkEeB61-rx2y6Qu4dBwyMpKPzLKJ9aXPNFMEhEQKVJhZaxtKpKUQhBrBujzBj5tECk75Kpxx6-8MiV9Q-b7TQf5t_Tl4cmwOXl2c9Ln6A74v7zN59xF2_NZbffAx5zrF40x-Q1Jr34f |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfGkIAX_g8KGxjEwx5IyR8ntiVeGNpUxrqHaUgTErJsx2nD2iRqG4n2iY_At-B78Uk4J2lYR5EmHlJF8eWSXM_nO_v8O4ReSRiSwW-VjjJe5BAS-g5XOnQ8SaiOuPaksoFi_zjqfSKHZ-HZBnq73AtT40O0E262Z1T22nZwOyF9oZerr8OuRbGEgP26rehdBVQn_p81BDds6uVRMDaENbhCNo-nvXVlNLqWpek6R_PvfMkGVXTVoa1GpIM76MvyW-pElPNuOVNdvbgE8_i_H3sX3W5cVfyu1q17aMNk99GNfrMY_wD9PJFZnI_ThYlf42IIwyEOcFUFBOcJTrN8Vi7KsVQ4X-QDW_Y-zXAxKqd4ks7Kb6ltsTkhcAEUZ9zsBJtfJgGnGtsNN8XUxG9AgJOqQNAcy0E1UwDGGu_9-v7DLkDgLM_gtJfHg3N41mgOmpqP5UN0erB_-r7nNHUfHNAO6joeJ4GUksQ-NT43hNMwVHbDrEddTX2ZaMNcyf2YRUwzbgLDdKxDJmWUaMKDLbQJzzOPETY8lIEPGqdt5cEwAaZcUWY4VcaVgddBu8u_X-gGE92W5hiJZWwEcheV3DvoZUta1EAg64h2QIeAlf211Q7BAWIQ89GQQrsXddD2UrtEYyumwncZZTawhNd50TZDL7eSk5nJy6mAqBoMpRuyoIMe1crYvoVvIQkZB-Z0RU1bAosgvtqSpcMKSTyyqYkEeO7XCr1yy6gs4FBwiKkRbqClS4wrWKyoINwjgifciEiZhMdJCHGs7qDPa_jUcaRowKuGDb_iwqz0FZnvVj3k39IXe4e96uTJ1Umfo5u90_6ROPpw_PEpugXuMKvTO7fR5mxSmh1wOWfqWWVZfgPMLYI6 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbGkCZu-P8pbGAQF7sgJT9ObIsrxlaVwSY0DWlCkyzbcdqwNonaRmK94hF4C96LJ-E4ScM6ijRxkSqKnZPE_Xx8jn38HYReShiSwW6VjjJe5BAS-g5XOnQ8SaiOuPakso7iwWHU_0z2T8KTNfRmsRem5odoJ9xsz6j0te3gRZxc6OTq67BrSSzBX79OIpdZSO8e-X-WENywSZdHQdcQ1tAK2TCe9talwehalqar7My_wyUbUtFle7YakHq30OniU-o4lLNuOVNdPb_E8vif33ob3WwMVfy2RtYdtGayu2jjoFmKv4d-Hskszsfp3MSvcDGEwRAHuMoBgvMEp1k-K-flWCqcz_OBTXqfZrgYlVM8SWflt9SW2IgQuACwGTf7wM4vVwGTGtvtNsXUxK-h_SZVeqBzLAfVPAGoarzz6_sPu_yAszyD034eD87gWaNzwGk-lvfRcW_v-F3fabI-OIAN6joeJ4GUksQ-NT43hNMwVHa7rEddTX2ZaMNcyf2YRUwzbgLDdKxDJmWUaMKDB2gdnmceIWx4KAMf8KZt3sEwAaFcUWY4VcaVgddB24t_X-iGEd0m5hiJhWcE7S6qdu-gF23VoqYBWVVpCyAEouyvzXUI5g8Dj4-GFMq9qIM2F-ASjaaYCt9llFm3El7neVsMfdy2nMxMXk4F-NSgJt2QBR30sMZi-xa-JSRkHITTJZS2FSx_-HJJlg4rHvHIBiYSkLlX43npllFZwKHgEFMj3EBLlxhXsFhRQbhHBE-4EZEyCY-TELxY3UFfVsipvUjRUFcNG3nFhTnpKwrfrjrIv1tf7Oz3q5PHV6_6DG182u2Jj-8PPzxBN8AWZnVs5yZan01KswX25kw9rfTKbxpCgPI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized%2C+phase+3+trial+of+inotuzumab+ozogamicin+plus+rituximab+versus+chemotherapy+plus+rituximab+for+relapsed%2Frefractory+aggressive+B%E2%80%90cell+non%E2%80%90Hodgkin+lymphoma&rft.jtitle=British+journal+of+haematology&rft.au=Dang%2C+Nam+H.&rft.au=Ogura%2C+Michinori&rft.au=Castaigne%2C+Sylvie&rft.au=Fayad%2C+Luis+E.&rft.date=2018-08-01&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=182&rft.issue=4&rft.spage=583&rft.epage=586&rft_id=info:doi/10.1111%2Fbjh.14820&rft.externalDBID=10.1111%252Fbjh.14820&rft.externalDocID=BJH14820 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |